Results 161 to 170 of about 1,263,858 (270)

Assessment of a high-order shock-capturing central-difference scheme for hypersonic turbulent flow simulations

, 2021
Donatella Passiatore, CINELLA, Paola, GIUSEPPE, Pascazio, Luca Sciacovelli   +3 more
openalex   +2 more sources

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

Bending Energy Schemes for Discrete-Spring-Network Structural Modelling of Red Blood Cells. [PDF]

Int J Numer Method Biomed Eng
Ehi-Egharevba O, Chen M, Boyle FJ.
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Salivary IgG Antibody Response to SARS-CoV-2 as a Non-Invasive Assessment of Immune Response-Differences Between Vaccinated Children and Adults. [PDF]

Biomedicines
Badano MN, Keitelman I, Pereson MJ, Aloisi N, Sabbione F, Baré P.   +5 more
europepmc   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Quantifying the effects of pseudonymisation on epidemiological research reliability: a tailored evaluation using a clinical data warehouse. [PDF]

BMC Med Inform Decis Mak
Cohen A, Jacob Y, Chatellier G, Jean C, Playe B, Mouchet A, Audureau E, Boutet A, Bey R.   +8 more
europepmc   +1 more source

De-Risking Industrial Decarbonization: Insights from the German Carbon Contracts for Difference Scheme

Robin Blömer, Johannes Eckstein
openalex   +1 more source

On the strong stability of differential equations and difference schemes [PDF]

, 2005
Boško S. Jovanović
openalex   +1 more source